PEDIATRICS Vol. 42 No. 5 November 1968, pp. 793-802
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnstone, D. E.
Right arrow Articles by Dutton, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Johnstone, D. E.
Right arrow Articles by Dutton, A.

THE VALUE OF HYPOSENSITIZATION THERAPY FOR BRONCHIAL ASTHMA IN CHILDREN—A 14-YEAR STUDY

Douglas E. Johnstone M.D.1 and Arthur Dutton Ph.D.1

1 Department of Pediatrics and the Statistics Section of the Department of Radiation Biology and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, New York

The clinical course of 210 children with perennial bronchial asthma was followed in a prospective controlled study in which one half of the children received placebo injections while the other half received conventional hyposensitization therapy. Of the 130 children still under observation at the time of their sixteenth birthday, 22% of the placebo-treated children were free of asthma compared to 72% of the treated children. In the treated group the rate of loss of asthma may be related to the dose of antigen received in hyposensitization therapy. Whereas 66% of the "1/5,000" group were free of asthma at the end of the study, 78% of the "highest tolerated dose" group were symptom free in their sixteenth year. The likelihood of a child outgrowing asthma was not significantly influenced by his sex, age of onset, or severity of his symptoms when first seen. A previous history of hay fever increased the likelihood of a child's asthma persisting into adolescence.

Submitted on February 1, 1968
Accepted on June 14, 1968




This article has been cited by other articles:


Home page
 JAMAHome page
M. Plaut
Immune-Based, Targeted Therapy for Allergic Diseases
JAMA, December 19, 2001; 286(23): 3005 - 3006.
[Full Text] [PDF]

Home page
 ThoraxHome page
G. Passalacqua, G. Ciprandi, and G. W. Canonica
United airways disease: therapeutic aspects
Thorax, October 1, 2000; 55(90002): 26S - 27.
[Full Text]

Home page
 NEJMHome page
N. F. Adkinson
Immunotherapy for Allergic Rhinitis
N. Engl. J. Med., August 12, 1999; 341(7): 522 - 524.
[Full Text]

Home page
 NEJMHome page
N. F. Adkinson, P. A. Eggleston, D. Eney, E. O. Goldstein, K. C. Schuberth, J. R. Bacon, R. G. Hamilton, M. E. Weiss, H. Arshad, C. L. Meinert, et al.
A Controlled Trial of Immunotherapy for Asthma in Allergic Children
N. Engl. J. Med., January 30, 1997; 336(5): 324 - 332.
[Abstract] [Full Text] [PDF]